Poultry Fires, but the Quarter's Profit Hinges on Gates Foundation

Poultry division delivered a genuine 48% YoY surge (₹60+ Cr, up from ~₹45–48 Cr), driven by market penetration and traction from the newly approved LPAI vaccine and companion products like biosecurity aids and feed supplements. But consolidated revenue declined 8.2% YoY to ₹77.2 Cr — a ₹20+ Cr drag from international weakness (Nepal, Africa) that management's guiding narrative of 'balanced 50/50 revenue mix' has failed to deliver. And the reported ₹96.7 Cr net profit, which appears to be a blowout, is almost entirely a one-time exceptional gain: a ₹55–60 Crore (USD 7 million) accounting entry from the Gates Foundation restructuring Hester Africa's debt (reducing USD 12 million to USD 5 million and waiving interest). Strip that out, and underlying profit collapses to roughly ₹36–42 Crore — still respectable, but a far cry from the 459% headline.

The company reported a 100% net profit margin (₹96.7 Cr PAT on ₹77.2 Cr revenue). This is impossible on operations alone. Management disclosed: 'Consolidated profitability during the quarter includes an exceptional accounting gain arising from the amendment of the soft loan extended to Hester Africa by the Gates Foundation.' The gain: USD 12 million debt reduced to USD 5 million, interest waived going forward. That's a ₹55–60 Crore non-cash benefit in a single quarter, accounting for ~60% of reported PAT. Without it, the quarter is operationally weak — consolidated revenue down, Animal Healthcare delayed, and international operations still loss-making.

The market's reaction on day 1 was a modest -1.06% decline (from ₹2,478.2 pre-result to ₹2,452), with 53.5% delivery suggesting some rotation out of speculative positions. The stock now trades at ₹2,452, sitting comfortably above all three major moving averages (SMA20 ₹2,375, SMA50 ₹2,180, SMA200 ₹1,720), signaling a structurally bullish trend. However, it is 8.22% below its all-time high of ₹2,671.6, suggesting the market has already discounted near-term disappointment. RSI at 43.7 (neutral) shows neither overbought nor oversold conditions — room to move either direction depending on next quarter's execution.

Ownership flows are headwinds. FII holdings have shrunk to 0.38% (latest), down from 0.87% a year ago — a 49 bps decline — and -13 bps quarter-on-quarter. This suggests foreign institutional capital has been trimming exposure over the past year, even as the stock rallied 96% off its 52-week low. DII holdings are negligible at 0.01%, signaling domestic institutions are also not aggressively backing the story. Promoter ownership remains steady at 53.73%, showing no insider selling but also no buying conviction near the all-time highs. The combination — falling FII, low DII, steady promoter, and modest post-result price decline — reads as the market digesting the earnings and finding the stock fairly valued to slightly expensive on an organic basis.

The day-1 price action and the FII trimming align with the fundamental story: headline PAT growth of 459% is a mirage (exceptional gain). Organic growth is much weaker, and international drag persists. The market is not yet punishing the stock sharply, but the absence of buying (especially from FII) suggests skepticism about near-term catalysts. The next quarter's cash flow and Animal Healthcare tender progress will be make-or-break for investor confidence.

From here, the key metric is adjusted consolidated PAT (net of any exceptional gains). Reported profit is a distraction; organic profit is the truth. If Q2 adjusted PAT comes in at ₹35–40 Cr (low-to-mid 30s range), the company is treading water despite Poultry growth. If it rebounds to ₹45+ Cr, management has a real story. Paired with that: consolidated revenue growth. If revenue is still negative YoY in Q2, the international headwind is not timing, it's structural, and the 50/50 mix goal is a fantasy. Close the quarter watching these two numbers; everything else is narrative.